These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18083295)

  • 1. Editorial comment on: validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Lopez-Beltran A; Montironi R
    Eur Urol; 2008 Dec; 54(6):1311-2. PubMed ID: 18083295
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: validation of the contemporary Epstein criteria for insignificant prostate cancer in European men.
    Salonia A
    Eur Urol; 2008 Dec; 54(6):1312-3. PubMed ID: 18083297
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Jeldres C; Suardi N; Walz J; Hutterer GC; Ahyai S; Lattouf JB; Haese A; Graefen M; Erbersdobler A; Heinzer H; Huland H; Karakiewicz PI
    Eur Urol; 2008 Dec; 54(6):1306-13. PubMed ID: 18083294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Loeb S; Roehl KA; Thaxton CS; Catalona WJ
    Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Shariat SF; Svatek RS
    Eur Urol; 2009 Mar; 55(3):626-8. PubMed ID: 18499336
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictive models in diagnosing indolent cancer.
    Bangma CH; Roobol MJ; Steyerberg EW
    Cancer; 2009 Jul; 115(13 Suppl):3100-6. PubMed ID: 19544551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment on: development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
    Kattan MW
    Eur Urol; 2008 Sep; 54(3):611. PubMed ID: 18207318
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
    Chun FK; Briganti A
    Eur Urol; 2008 Sep; 54(3):702. PubMed ID: 18403097
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: The feasibility of prostate cancer detection by triple spectroscopy.
    Da Pozzo LF
    Eur Urol; 2009 Feb; 55(2):383-4. PubMed ID: 18359149
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: Molecular cancer phenotype in normal prostate tissue.
    Füssel S
    Eur Urol; 2009 Apr; 55(4):891. PubMed ID: 18501498
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Malavaud B
    Eur Urol; 2008 Sep; 54(3):515-6. PubMed ID: 18585850
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Rittmaster R
    Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
    Giannarini G
    Eur Urol; 2009 Mar; 55(3):608. PubMed ID: 18597926
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
    Lange PH
    Eur Urol; 2009 Mar; 55(3):609. PubMed ID: 18597925
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
    Ahyai SA; Eichelberg C; Isbarn H; Zacharias M; Briganti A; Huland H; Chun FK
    Eur Urol; 2009 Mar; 55(3):607. PubMed ID: 18597922
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series.
    Isbarn H; Jeldres C; Budäus L; Salomon G; Schlomm T; Steuber T; Chun FK; Ahyai S; Capitanio U; Haese A; Heinzer H; Huland H; Graefen M; Karakiewicz P
    Urology; 2009 Mar; 73(3):615-9. PubMed ID: 19010520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.